Successful treatment with atezolizumab combination chemotherapy in a patient with high‐grade fetal adenocarcinoma of the lung: A case report

High‐grade fetal lung adenocarcinoma (H‐FLAC) is a rare tumor, with little known of its response to chemotherapy with or without an immune checkpoint inhibitor or of its molecular profile. We report the first case of a 56‐year‐old man with stage IV H‐FLAC who was successfully treated with carboplati...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujimoto, Kana, Watanabe, Satomi, Yasuda, Yuto, Date, Emi, Kawabata, Yasuhiro, Kanemura, Hiroaki, Takahama, Takayuki, Yonesaka, Kimio, Iizuka, Norishige, Takahashi, Ken‐ichi, Kawakami, Osamu, Ozaki, Tomohiro, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9834689/
https://www.ncbi.nlm.nih.gov/pubmed/36495048
http://dx.doi.org/10.1111/1759-7714.14768
Descripción
Sumario:High‐grade fetal lung adenocarcinoma (H‐FLAC) is a rare tumor, with little known of its response to chemotherapy with or without an immune checkpoint inhibitor or of its molecular profile. We report the first case of a 56‐year‐old man with stage IV H‐FLAC who was successfully treated with carboplatin plus nab‐paclitaxel in combination with atezolizumab. In addition, the tumor was found to be positive for amplification of the human epidermal growth factor receptor 2 gene.

Ejemplares similares